Collaborators of Tryp Therapeutics from the University of Michigan will present two scientific posters at the Society for Neuroscience conference.
The first study found that intravenous (IV) psilocybin reduced chronic pain in a rat model of fibromyalgia, the first to explore psilocybin use in fibromyalgia treatment.
The second found that a 60-minute intravenous infusion brought the rats into a psychedelic state.
Tryp Therapeutics CEO, Jim Gilligan, stated: “We are excited our collaborators at the University of Michigan are presenting the results of our two recent studies.
“The first study explored intravenous psilocybin and its effect in a recognized rat model of fibromyalgia. This model exhibits increased sensitivity to touch and hypersensitivity to elevated temperatures.
“Administration of a single intravenous infusion of psilocybin resulted in a decrease in both pain and heat sensitivity persisting until the end of the study (28 days). Tryp is the first company to pursue the use of psychedelics in nociplastic pain indications including fibromyalgia.
“These results support the potential clinical utility of psilocybin-assisted therapy in the treatment of patients with fibromyalgia.
“The second study demonstrated a change in EEG recordings coincident with achieving the psychedelic state. Rats received a continuous intravenous infusion of psilocybin over a period of 60 minutes while EEG data were simultaneously monitored.
“The results demonstrate the ability to detect changes in EEG patterns coincident with attaining the psychedelic state. In addition, upon cessation of the infusion a return to baseline EEG patterns correlated with decreasing blood levels of psilocin.”
Gilligan said that the study will help facilitate Tryp’s programme to utilise EEG recordings to optimise dose and infusion rates of IV psilocin (TRP-8803) in planned upcoming clinical trials.
Details of the poster presentations are:
Title: Psilocybin Attenuates Mechanical Allodynia and Thermal Hyperalgesia in a Rodent Model of Formalin-Induced Chronic Pain
Presenting Author: Dr Nick Kolbman, University of Michigan
Co-authors: B. H. Silverstein,1, T. Liu,1 P. Guzzo,2 J. P. Gilligan,2 G. A. Mashour,1, G. Vanini,1 D. Pal1
(1 University of Michigan, 2 Tryp Therapeutics)
The study results demonstrated that a single intravenous dose of psilocybin can attenuate mechanical allodynia and thermal hyperalgesia for up to four weeks post dose.
Title: Intravenous Psilocybin Alters Brain Network Dynamics in Rats
Presenting Authors: B.H. Silverman, University of Michigan
Co-authors: N. Koblman1,2,3, T. Liu1, P. Guzzo6, J. Gilligan6, G. A. Mashour1,2,3,4, G. Vanini 1,2,4, D. Pal1,2,4,5;
(1Dept. of Anesthesiol., 2Ctr. for Consciousness Sci., 3Dept. of Pharmacol., 4Neurosci. Grad. Program, 5Dept. of Mol. & Integrative Physiol., Univ. of Michigan, Ann Arbor, MI; 6Tryp Therapeut.)
This study demonstrated a change in EEG recordings in rats receiving an IV infusion of psilocybin coincident with achieving the psychedelic state.
